Total Valuation
Arcadia Biosciences has a market cap or net worth of €1.31M. The enterprise value is €341.10K.
Market Cap€1.31M
Enterprise Value€341.10K
Share Statistics
Arcadia Biosciences has 2,181,715 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,181,715
Owned by Insiders―
Owned by Institutions12.56%
Financial Efficiency
Arcadia Biosciences’s return on equity (ROE) is -0.56 and return on invested capital (ROIC) is -222.75%.
Return on Equity (ROE)-0.56
Return on Assets (ROA)-0.36
Return on Invested Capital (ROIC)-222.75%
Return on Capital Employed (ROCE)-2.23
Revenue Per Employee539.78K
Profits Per Employee-259.89K
Employee Count9
Asset Turnover0.74
Inventory Turnover2.56
Valuation Ratios
The current PE Ratio of Arcadia Biosciences is ―. Arcadia Biosciences’s PEG ratio is 0.02.
PE Ratio―
PS Ratio0.56
PB Ratio0.65
Price to Fair Value0.65
Price to FCF-0.57
Price to Operating Cash Flow-0.22
PEG Ratio0.02
Income Statement
In the last 12 months, Arcadia Biosciences had revenue of 4.86M and earned -2.34M in profits. Earnings per share was -1.71.
Revenue4.86M
Gross Profit1.76M
Operating Income-9.99M
Pretax Income-2.33M
Net Income-2.34M
EBITDA-2.30M
Earnings Per Share (EPS)-1.71
Cash Flow
In the last 12 months, operating cash flow was -4.25M and capital expenditures 0.00, giving a free cash flow of -4.25M billion.
Operating Cash Flow-4.25M
Free Cash Flow-4.25M
Free Cash Flow per Share-1.95
Dividends & Yields
Arcadia Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.18
52-Week Price Change0.00%
50-Day Moving Average3.72
200-Day Moving Average3.72
Relative Strength Index (RSI)100.00
Average Volume (3m)0.00
Important Dates
Arcadia Biosciences upcoming earnings date is Aug 19, 2026, After Close (Confirmed).
Last Earnings DateMay 14, 2026
Next Earnings DateAug 19, 2026
Ex-Dividend Date―
Financial Position
Arcadia Biosciences as a current ratio of 3.09, with Debt / Equity ratio of 0.00%
Current Ratio3.09
Quick Ratio2.50
Debt to Market Cap0.00
Net Debt to EBITDA0.11
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Arcadia Biosciences has paid 8.00K in taxes.
Income Tax8.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Arcadia Biosciences EV to EBITDA ratio is -1.07, with an EV/FCF ratio of -0.52.
EV to Sales0.50
EV to EBITDA-1.07
EV to Free Cash Flow-0.52
EV to Operating Cash Flow-0.52
Balance Sheet
Arcadia Biosciences has €3.72M in cash and marketable securities with €0.00 in debt, giving a net cash position of €3.72M billion.
Cash & Marketable Securities€3.72M
Total Debt€0.00
Net Cash€3.72M
Net Cash Per Share€1.71
Tangible Book Value Per Share€3.00
Margins
Gross margin is 34.49%, with operating margin of -205.74%, and net profit margin of -48.15%.
Gross Margin34.49%
Operating Margin-205.74%
Pretax Margin-47.98%
Net Profit Margin-48.15%
EBITDA Margin-47.32%
EBIT Margin-47.98%
Analyst Forecast
The average price target for Arcadia Biosciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―